FDA Testosterone Label Change 2026: What Moved on Prostate Cancer and Age-Related Low T
FDA requested class-wide testosterone label updates on June 18, 2026: what moved on prostate cancer, age-related low T, BPH, and which markers to track.
FDA Testosterone Label Change 2026: What Moved on Prostate Cancer and Age-Related Low T **On June 18, 2026, the U.S. Department of Health and Human Services, acting through the FDA, formally requested class-wide prescribing information updates for testosterone replacement therapy products, with news coverage running through June 23. The request has three parts: remove the limitation of use added in 2015 stating that safety and effectiveness were not established in men with age-related hypogonadism, narrow the prostate cancer contraindication so that testosterone is contraindicated only in men with metastatic prostate cancer rather than any known or suspected prostate cancer, and revise the benign prostatic hyperplasia warnings after a review found no worsening of symptoms in mild to moderate disease. The primary evidence driver is the TRAVERSE trial, which randomized 5,246 men and found testosterone noninferior to placebo for major adverse cardiac events. These are requested labeling updates to manufacturers, not a change to who may be prescribed testosterone, and every treatment decision still belongs with a licensed clinician.** Regulatory labeling is one of the few places where the state of the evidence gets written down in a form that patients actually see. When a line comes off a label, it changes the conversation a prescriber and a patient start from. It does not settle the underlying science, and it does not make anything appropriate for any individual. The June 2026 testosterone request is a good example of both halves of that statement, because it moves three specific pieces of language while the Endocrine Society simultaneously reaffirmed that long-term safety questions remain open. This article walks through exactly what was requested, what evidence drove it, what the February 2025 action set up beforehand, and which markers people commonly log when they want a provider-ready record. MyProtocolStack is a tracking and education tool. Nothing here is medical advice.
What the June 2026 Request Actually Asks For
On June 18, 2026, HHS announced that the FDA had requested updates to the prescribing information for testosterone replacement therapy products as a class. The action followed a review of newer clinical evidence and a reanalysis of existing data. Three items were named.
The first is the limitation of use for age-related hypogonadism. Since 2015, testosterone labels have carried language stating that the safety and effectiveness of testosterone replacement in men with age-related hypogonadism had not been established. That language was added at a time when evidence of benefit was limited and questions had been raised about possible cardiovascular risk, following a 2014 FDA advisory committee meeting that led the agency to call for a dedicated safety trial. The request asks that the limitation be removed.
The second is the prostate cancer contraindication. Current labels list known or suspected prostate cancer as a contraindication. Under the requested revision, testosterone replacement therapy would be contraindicated only in men with metastatic prostate cancer. HHS pointed to clinical trial and epidemiologic data that have generally not shown an increased risk of prostate cancer in men receiving the therapy.
The third is the benign prostatic hyperplasia warning. Labels currently caution that testosterone may worsen symptoms of an enlarged prostate. The FDA review found that available clinical trial data have not shown worsening symptoms among men with mild to moderate BPH. Evidence remains more limited in men with severe symptomatic disease, and the revised labeling would continue to recommend close monitoring in that group, which is why this is described as a revision rather than a removal.
|---|---|---|
One point deserves emphasis because it is the easiest thing to get wrong when reading coverage of this story. A request to manufacturers to update prescribing information is not the same as a change to eligibility. It does not by itself expand who can receive testosterone, it does not create a new indication, and it does not alter the clinical judgment a prescriber applies to an individual patient. It changes what is printed.
The Prostate Cancer Change Is the One People Are Talking About
Of the three items, the prostate cancer revision is the one that most changes the shape of the label. Moving from known or suspected prostate cancer to metastatic prostate cancer is a substantial narrowing of the contraindication, and it reflects a body of clinical trial and epidemiologic research that has generally not found a higher prostate cancer risk in men using testosterone therapy.
The strongest human trial evidence in this area comes from the prostate safety substudy nested inside TRAVERSE, published in JAMA Network Open in December 2023. Across 14,304 person-years of follow-up in 5,204 analyzed participants, adjudicated high-grade prostate cancer occurred in 5 of 2,596 men in the testosterone group, or 0.19 percent, and in 3 of 2,602 men in the placebo group, or 0.12 percent. The hazard ratio was 1.62 with a 95 percent confidence interval of 0.39 to 6.77 and a P value of 0.51. The incidences of any prostate cancer, acute urinary retention, invasive prostate surgical procedures, prostate biopsy, and new pharmacologic treatment for lower urinary tract symptoms also did not differ significantly between groups.
Two caveats belong right next to that finding, and honest reporting requires both. First, the substudy population was deliberately low risk. Men were excluded if they had a PSA concentration above 3.0 ng/mL, or above 1.5 ng/mL while taking a 5-alpha-reductase inhibitor, an International Prostate Symptom Score above 19, a prostate nodule or induration on digital rectal examination, or a prior prostate cancer diagnosis. Findings from a population screened that carefully do not automatically transfer to men who would have been screened out. Second, the authors themselves cautioned that because the number of prostate cancer events was small, the findings should not be interpreted to imply that prostate cancer risk in the testosterone and placebo groups was similar. The point estimate actually sat above 1.0, with a confidence interval running from 0.39 to 6.77. A result that wide is a statement about what the study could detect, not a demonstration of equivalence.
That is the difference between a label change and a settled question. The label reflects a regulatory judgment about how a class of products should be framed. The underlying uncertainty about long-term prostate outcomes is still there, and it is why monitoring stays in the conversation regardless of what the printed warning says.
The Evidence Driver: What TRAVERSE Did and Did Not Show
TRAVERSE is the trial doing most of the work behind both the 2025 and 2026 actions. It randomized 5,246 men aged 45 to 80 who reported symptoms of hypogonadism, had two fasting testosterone measurements below 300 ng/dL, and had preexisting cardiovascular disease or were at high risk for it. Participants received a daily transdermal 1.62 percent testosterone gel or placebo gel. Mean treatment duration was 21.7 months and mean follow-up was 33.0 months. It was published in the New England Journal of Medicine in June 2023.
The primary result was a noninferiority finding on major adverse cardiac events. A first primary cardiovascular end-point event occurred in 182 patients, or 7.0 percent, in the testosterone group, and in 190 patients, or 7.3 percent, in the placebo group, with a hazard ratio of 0.96 and a 95 percent confidence interval of 0.78 to 1.17. That is the finding regulators leaned on when concluding that the 2015 limitation of use was no longer warranted.
The trial also reported a higher incidence of three secondary events in the testosterone group. As reported in the trial publication, atrial fibrillation occurred in 3.5 percent of the testosterone group versus 2.4 percent of placebo, acute kidney injury in 2.3 percent versus 1.5 percent, and pulmonary embolism in 0.9 percent versus 0.5 percent. TRAVERSE also found a higher rate of clinical bone fractures among testosterone-treated men, though not of major osteoporotic fractures, and the Endocrine Society's July 2026 statement cites both the fracture finding and the pulmonary embolism signal as unresolved safety questions.
These were secondary observations in a trial designed and powered to answer a different question. A 2026 European expert panel position statement published in Andrology characterized the arrhythmia finding as a minor but statistically significant increase, and noted that concurrent COVID-19 infection within the cohort complicated interpretation of the kidney injury and venous thromboembolism signals. None of this supports a conclusion about any individual, but it is part of the record, and leaving it out would misrepresent what the trial showed.
The scope limit matters too. TRAVERSE enrolled men with symptomatic hypogonadism and confirmed low fasting testosterone. Its reassurance applies to men in whom therapy is indicated, not to men without an indication.
Two Steps, Not One: February 2025 Set This Up
The June 2026 request is the second half of a two-step shift, and the two steps moved in different directions on different markers. Reading them together is what makes the practical picture clear.
On February 28, 2025, the FDA issued class-wide labeling changes for testosterone products after reviewing TRAVERSE and the results of required postmarket ambulatory blood pressure monitoring studies. That action added the TRAVERSE results to all testosterone product labels and removed the boxed warning language relating to increased risk of adverse cardiovascular outcomes. At the same time, because the completed ambulatory monitoring studies confirmed a class-wide increase in blood pressure with testosterone products, the FDA added product-specific blood pressure information for products with completed studies and required that a blood pressure warning be added where none existed.
Critically, the February 2025 action retained the limitation of use language for age-related hypogonadism. That is precisely the line the June 2026 request asks to remove. So the sequence reads: February 2025 de-emphasized cardiovascular risk in the boxed warning while elevating blood pressure, and June 2026 asks to drop the age-related hypogonadism limitation and narrow the prostate language.
|---|---|---|
If you are trying to summarize the net effect in one sentence for someone who does not follow regulatory news: the cardiovascular alarm on the label got quieter, the blood pressure line got louder, and the prostate and age-related restrictions got narrower.
What the Endocrine Society Said in July 2026
Regulatory framing and clinical practice standards are not the same thing, and in July 2026 the gap between them was visible. On July 16, 2026, the Endocrine Society issued a statement reinforcing the diagnostic standards in its existing clinical practice guideline rather than introducing a new one. It said that a hypogonadism diagnosis should be made by a healthcare provider based on at least two early-morning, fasting testosterone tests, with a common clinical threshold near 300 ng/dL, and that assays certified by the CDC Hormone Standardization program improve comparability because certification means the assays have been standardized and harmonized.
The statement also made a point that bears directly on the label change itself: terms such as age-related, late-onset, and functional hypogonadism are difficult to define operationally and blur the line between a treatable disease and normal aging. On safety, it said that screening and monitoring are needed if testosterone therapy is initiated, that long-term safety including for prostate cancer remains unestablished because prostate cancer develops slowly and trials may not have followed men long enough, and that risk assessment before starting treatment and careful monitoring during treatment remain essential. It called for a long-term Men's Health Initiative, analogous to the Women's Health Initiative, to close the remaining evidence gaps.
The takeaway for anyone reading the label news is straightforward. A narrower printed contraindication did not come with a narrower monitoring expectation. If anything, the professional guidance leans harder on standardized diagnosis and consistent follow-up.
This pattern is not unique to testosterone. The [2026 menopause hormone therapy black box removal](/blog/menopause-hrt-2026-black-box-biomarkers-women) followed a similar shape, where a prominent class-level warning came off while the individualized clinical questions stayed exactly where they were.
What to Track: The Markers This Two-Step Shift Elevates
None of the following is a recommendation to test, start, stop, or change anything. It is a list of what is commonly discussed and logged around testosterone therapy, organized so you can bring a clean record to the person qualified to interpret it. What follows a labeling shift is a record-keeping question, and that is squarely inside what a tracking tool can help with.
The single most valuable habit here is consistency of conditions. An early-morning fasting draw is not comparable to a mid-afternoon one, and comparing them produces a trend line that means nothing. The comparable version is same time of day, same fasting state, and same lab where possible. You can browse plain-language explanations of each test in the full [biomarker library](/biomarkers), and the [testosterone panel guide](/blog/testosterone-panel-guide) covers which values are typically pulled together and why.
### What the label will and will not tell you at the counter
Once manufacturers implement the requested revisions, a label will carry no age-related hypogonadism limitation, a prostate cancer contraindication that names metastatic disease specifically, and a softened benign prostatic hyperplasia caution. What that label will not say is that anything about an individual reader's own risk profile changed, because nothing about it did. A label describes a class of products. It does not describe a person.
The two-step shift also indicates which numbers deserve more attention in a log and which deserve less weight as a headline. Blood pressure moved up, added as a required warning in February 2025 on the strength of ambulatory monitoring studies. The cardiovascular boxed warning moved down, removed in that same action. That is not a reason to stop caring about cardiovascular markers. It is a signal that a class-level alarm was replaced by a more specific one, and the specific one is a number that can be measured at home and logged. For anyone whose picture also includes metabolic medications, the interaction between [GLP-1 therapy and testosterone](/blog/glp1-testosterone) is useful context for why panels are pulled together rather than piecemeal.
### Keeping a record that survives a label change
Regulatory framing will keep moving. It moved in February 2025, it moved again in June 2026, and the Endocrine Society's call for a long-term Men's Health Initiative is an explicit acknowledgment that the evidence base is still being built. The thing that does not go stale is a clean longitudinal record collected under consistent conditions.
Practically, that means logging every draw with its date, time, fasting state, and lab, keeping blood pressure readings between visits rather than relying on a single in-office measurement, recording a full panel together rather than in fragments, and reviewing the trend rather than reacting to any single value. When the framing shifts again, the conversation can start from data rather than from scratch. For broader background on how these markers fit together, the [testosterone optimization guide](/blog/testosterone-optimization-guide) covers the landscape in more depth.
MyProtocolStack organizes and visualizes that history. It does not interpret it, it does not diagnose, and it is not a substitute for your clinician's judgment. The goal is simple: bring good, consistent data to the people qualified to read it.
[Keep your hormone panel, blood pressure log, and lab history in one provider-ready record with MyProtocolStack.](/auth/login?mode=signup)
Frequently Asked Questions
What did the FDA change about testosterone labels in 2026?
On June 18, 2026, HHS, acting through the FDA, formally requested class-wide prescribing information updates for testosterone replacement therapy products, with news coverage running through June 23. The request has three parts: remove the limitation of use added in 2015 stating that safety and effectiveness were not established in men with age-related hypogonadism, narrow the prostate cancer contraindication so it applies only to men with metastatic prostate cancer instead of any known or suspected prostate cancer, and revise the benign prostatic hyperplasia warnings after a review found no worsening of symptoms in mild to moderate disease, with close monitoring still advised in severe disease. These are requested labeling updates to manufacturers, not a change to who may be prescribed testosterone.
Did the FDA remove the prostate cancer warning from testosterone labels?
Not removed, narrowed. Current labels list known or suspected prostate cancer as a contraindication. The requested revision would make testosterone contraindicated only in men with metastatic prostate cancer, on the basis that clinical trial and epidemiologic data have generally not shown an increased prostate cancer risk. The prostate safety substudy inside TRAVERSE found adjudicated high-grade prostate cancer in 5 of 2,596 men on testosterone, or 0.19 percent, versus 3 of 2,602 on placebo, or 0.12 percent, with a hazard ratio of 1.62 and a 95 percent confidence interval of 0.39 to 6.77. That substudy excluded men with PSA above 3.0 ng/mL, an International Prostate Symptom Score above 19, a prostate nodule or induration, or a prior prostate cancer diagnosis, and its authors cautioned that the small number of events means the results should not be read as showing similar risk between groups. The Endocrine Society stated in July 2026 that long-term prostate safety remains unestablished.
Does the 2026 label change mean more men can get testosterone?
No. These are requested labeling updates to manufacturers about what is printed in the prescribing information. They do not create a new indication, do not change prescribing eligibility, and do not alter the clinical judgment a prescriber applies to an individual patient. Separately, on July 16, 2026, the Endocrine Society reinforced that a hypogonadism diagnosis should be made by a healthcare provider based on at least two early-morning, fasting testosterone tests, ideally using an assay certified by the CDC Hormone Standardization program. Whether therapy is appropriate for anyone is a decision only a licensed clinician can make.
What is the TRAVERSE trial and what did it find?
TRAVERSE randomized 5,246 men aged 45 to 80 who reported symptoms of hypogonadism, had two fasting testosterone measurements below 300 ng/dL, and had preexisting or high-risk cardiovascular disease, to daily transdermal 1.62 percent testosterone gel or placebo, with mean treatment duration of 21.7 months and mean follow-up of 33.0 months. Published in the New England Journal of Medicine in June 2023, it found testosterone noninferior to placebo for major adverse cardiac events, with a first event in 182 patients, or 7.0 percent, of the testosterone group and 190 patients, or 7.3 percent, of placebo, hazard ratio 0.96, 95 percent confidence interval 0.78 to 1.17. The trial also reported a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group as secondary observations, plus a higher rate of clinical bone fractures. Its reassurance applies to men in whom therapy is indicated, not to men without an indication.
Which biomarkers are commonly tracked on testosterone therapy after these label changes?
The two-step labeling shift elevated blood pressure, which gained a required class-wide warning in the February 2025 action after ambulatory monitoring studies, and de-emphasized the cardiovascular boxed warning, which was removed in that same action. Markers commonly logged include blood pressure, PSA, hematocrit and hemoglobin, total and free testosterone, SHBG, estradiol using a sensitive assay, LH and FSH, and cardiometabolic context such as ApoB, LDL-C, and hs-CRP. The most important factor is consistency of conditions, meaning early-morning fasting draws at the same lab where possible, so the trend line is comparable over time. None of this is a recommendation to test or treat, and interpretation belongs with your clinician.
Sources
1. U.S. Department of Health and Human Services, "HHS Announces Requested Updates to Testosterone Therapy Product Labels," June 18, 2026. https://www.hhs.gov/press-room/fda-requests-updates-testosterone-therapy-labeling.html
2. U.S. Food and Drug Administration, "FDA issues class-wide labeling changes for testosterone products," February 28, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
3. Lincoff AM, Bhasin S, Flevaris P, et al. "Cardiovascular Safety of Testosterone-Replacement Therapy" (TRAVERSE). New England Journal of Medicine. 2023;389(2):107-117. https://doi.org/10.1056/NEJMoa2215025
4. Bhasin S, Travison TG, Pencina KM, et al. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 2023;6(12):e2348692. https://doi.org/10.1001/jamanetworkopen.2023.48692
5. Endocrine Society, "Statement on Testosterone Replacement Therapy," July 16, 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy
6. Urology Times, "HHS requests testosterone therapy label updates, citing new safety data." https://www.urologytimes.com/view/hhs-requests-testosterone-therapy-label-updates-citing-new-safety-data
7. U.S. News and World Report, "Testosterone Therapy Labels And Limits May Change Under FDA Proposal," June 23, 2026. https://www.usnews.com/news/health-news/articles/2026-06-23/testosterone-therapy-labels-and-limits-may-change-under-fda-proposal
8. European Expert Panel for Testosterone Research, "Cardiovascular safety of testosterone therapy, insights from the TRAVERSE trial and beyond: A position statement." Andrology. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12670475/
*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →